Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Kazia Therapeutics’ SEC paperwork can feel like reading a clinical protocol—hundreds of pages on glioblastoma trials, milestone payments, and cash-runway projections. If you need Kazia Therapeutics insider trading Form 4 transactions or want the Kazia Therapeutics annual report 10-K simplified, the sheer volume is daunting.
Stock Titan solves that problem. Our AI distills every document—whether a Kazia Therapeutics quarterly earnings report 10-Q filing, a 6-K update, or an Kazia Therapeutics 8-K material events explained—into plain-English highlights. Receive Kazia Therapeutics Form 4 insider transactions real-time, scan cash-burn trends, and compare trial spending across periods without hunting through footnotes. Need the Kazia Therapeutics proxy statement executive compensation? Our summaries call out option grants and performance milestones in seconds, turning dense biotech jargon into actionable context.
Investors use these insights to:
- Track R&D outlays and licensing revenue straight from the Kazia Therapeutics earnings report filing analysis
- Monitor management buying and selling via Kazia Therapeutics executive stock transactions Form 4
- Flag clinical-trial milestones or FDA feedback noted in 6-K and 8-K filings
- Quickly answer “How are paxalisib trial costs trending?” with understanding Kazia Therapeutics SEC documents with AI
All filings arrive in real time, fully searchable, and Kazia Therapeutics SEC filings explained simply—so you spend minutes, not hours, extracting what matters.
Kazia Therapeutics announced an in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 protein degrader program centered on lead compound NDL2. The company expects IND-enabling studies to start within
Kazia Therapeutics Ltd: This Schedule 13G/A discloses that Alumni Capital LP, Alumni Capital GP LLC and Ashkan Mapar are collectively reported as beneficially owning 178,591 American Depository Shares (ADSs), representing 9.99% of the class on the filing’s stated basis. The reported percentage is calculated using the issuer's representation of 1,609,108 ADSs outstanding and reflects an Ownership Limitation that prevents the Fund from acquiring ADSs that would raise ownership above 9.99%.
The filing clarifies that the Fund actually owns 28,409 ADSs as of the filing date but may be deemed to beneficially own additional ADSs pursuant to a Purchase Agreement (dated April 19, 2024), Commitment Warrants, Common Warrants (dated January 10, 2025) and a July 31, 2025 Securities Purchase Agreement. All three Reporting Persons share voting and dispositive power over the 178,591 ADSs. Signatures are dated 09/11/2025.
Kazia Therapeutics Ltd filed a Form D reporting a Regulation D, Rule 506(b) offering that raised $2,050,013, with $2,050,013 sold and $0 remaining. The filing lists four investors and identifies offered securities as equity, options/warrants, and securities issuable on exercise.
The notice discloses pre-funded warrants to purchase up to 204,547 ADSs, each ADS representing 500 ordinary shares, and each pre-funded warrant exercisable for one ADS at an exercise price of $0.0001 per ADS. The filing reports $0 in sales commissions and finders' fees, $0 of proceeds paid to named officers or directors, and was signed by CEO John Friend on 2025-08-14.
On 31 Jul 2025 Kazia Therapeutics (KZIA) entered a definitive agreement for a private placement expected to close on or about 4 Aug 2025. Investors will buy 14,204,500 ordinary shares at US$0.0176 per share and pre-funded warrants exercisable for up to 204,547 ADSs (1 ADS = 500 shares) at US$8.7999 per warrant, with a token exercise price of US$0.0001 per ADS. Warrant holders are limited to 9.99 % beneficial ownership unless they give 61-day notice to increase the cap.
The transaction should yield ~US$2 million net proceeds after expenses. Kazia intends to direct the funds toward ongoing clinical development of paxalisib (brain-penetrant PI3K/mTOR inhibitor) and EVT801 (VEGFR3 inhibitor) and for general corporate purposes. The securities were issued under Section 4(a)(2) and Rule 506 exemptions; Kazia must file a resale registration statement within 60 days of closing and keep it effective until investors no longer hold the securities.
No financial results or guidance were provided. Closing remains subject to customary conditions.
FAQ
What is the current stock price of Kazia Therapeuti (KZIA)?
What is the market cap of Kazia Therapeuti (KZIA)?
